Jeff Martini
- Palvella Therapeutics, Inc. (no department on record)
From the FY2024 NIH awards this investigator leads as contact PI. The department is the award's.
FY2024 NIH rank #31,520
- R01 Holder
- Early Career
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 78915278Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
NIH Funding · FY2024
Linked Award Amount
$479.6K
Full award amounts, FY2024
Award Records
1
Records listing this PI
Award-Linked Rank
#31,520
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2024 award records by amount
NIH award records listing Jeff Martini as a PI. Multi-PI records show the full award amount for context.
- 1R01FD008196-01A1R01Contact PISELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations$479.6Kaward amount
Award organization
Organizations that administered FY2024 awards listing Jeff Martini as a PI.
FY2024 award administered by Palvella Therapeutics, Inc. (PA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardPalvella Therapeutics, Inc.
- 2025$500K Cumulative Funding
- 2025$1M Cumulative Funding
- 2025R01 Grant Holder